drugset / Trial / NCT03786744
Allogenic Cord Blood Transfusion in Patients With Autism
Phase 1/2
Completed
20 enrolled
State-Financed Health Facility "Samara Regional Medical Center Dinasty"
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Autism is one of those disorders in Autism spectrum disorders (ASD), which characterized by social interaction abnormalities, impaired verbal and non-verbal communication, and repetitive, obsessive behavior, while the therapeutic effect of current treatments remains limited progress. The possible reason for ASD is neural hypoperfusion and immune deregulation. The Human Umbilical Cord Blood Mononuclear Cells (hUCB-MNCs) have been shown to have the ability to modulate the immune response and enhance angiogenesis, suggesting the novel and promising therapeutic strategy. In this study, the safety and efficacy of hUCB-MNCs infusion will be evaluated in patients with Autism.
Timeline
- Start
- 2018-10-12
- Primary completion
- 2019-10-12
- Completion
- 2019-12-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | hUCB-MNCs | Unknown | 20 cells/kg | — |
| Subject | hUCB-MNCs | Unknown | 50 cells/kg | — |